ABSTRACT Some patients with metastatic non-small-cell lung cancer (NSCLC) receiving anti-PD-1 or anti-PD-L1 immune checkpoint inhibitors (ICIs) progress at a few sites while disease elsewhere stays controlled, a pattern consistent with focal, oligo-acquired immune escape rather than systemic treatment failure. Ablating...
I. Massalha, A. Hijab, R. Zabit et al.· Oncoimmunology· 0 citations
EGFR exon 20 insertion mutations represent a distinct subset of non–small cell lung cancer (NSCLC) with limited sensitivity to earlier-generation EGFR tyrosine kinase inhibitors (TKIs). CLN081 (zipalertinib; TAS6417) is a novel covalent EGFR TKI under development with activity against EGFR exon 20 insertion variants. W...
Basil Dabbah, R. Gillis, Jaber Salim et al.· Frontiers in Oncology· 0 citations
In a large international real-world study of non-small cell lung cancer, a multimodal explainable AI model outperformed established biomarkers for immunotherapy outcome prediction and improved physician decision-making.
A. Prelaj, V. Mišković, Matteo Sacco et al.· Nature Medicine· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.